Skip to main content

Advertisement

Table 2 Clinical characteristics of 1839 study subjects according to the SNP rs9267551

From: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients

Characteristics CZ GHS
GG GC CC p GG GC CC p
n 966 90 4   694 82 3  
Males (%) 60.8 54.4 25.0 0.18 55.0 57.3 100.0 0.27
Age (years) 61.6 ± 11.2 62.1 ± 11.7 57.5 ± 12.7 0.73 62 ± 9 60 ± 9 68 ± 14 0.09
Age at diabetes diagnosis (years) 53 ± 12 55 ± 13 50 ± 6 0.35 49 ± 10 48 ± 9 53 ± 13 0.59
Diabetes duration (years) 8.6 ± 9.0 7.2 ± 8.8 8.0 ± 7.7 0.37 12.4 ± 8.8 11.9 ± 8.8 15.3 ± 5.0 0.74
BMI (kg/m2) 31.0 ± 6.1 31.2 ± 6.9 33.7 ± 5.8 0.65 30.8 ± 5.1 31.7 ± 5.3 31.2 ± 3.7 0.34
HbA1c (%) 7.48 ± 1.63 8.03 ± 1.92 8.16 ± 1.92 0.03 8.57 ± 1.88 8.68 ± 1.87 9.10 ± 2.38 0.79
Total cholesterol (mg/dl) 186.9 ± 44.3 192.3 ± 42.0 213.7 ± 43.2 0.26 188.4 ± 47.7 182.7 ± 41.6 181.3 ± 68.6 0.56
HDL cholesterol (mg/dl) 46.1 ± 13.9 47.3 ± 12.9 52.2 ± 13.8 0.51 44.9 ± 13.6 44.6 ± 12.2 43.0 ± 6.1 0.95
Triglycerides (mg/dl) 158.1 ± 95.4 156.7 ± 133.6 105.7 ± 40.9 0.43 155.1 ± 101.5 149.5 ± 93.1 126.7 ± 92.4 0.70
Glucose-lowering therapy (%) 65.7 68.9 50.0 0.66 84.1 84.1 100.0 0.75
Anti-hypertensive therapy (%) 74.1 66.7 75.0 0.31 73.8 82.8 66.7 0.19
Anti-dyslipidemic therapy (%) 41.7 31.1 0.00 0.03 47.8 51.2 66.7 0.68
Ever smoked (%) 48.1 47.8 50.0 0.99 36.6 34.1 33.3 0.90
  1. CZ Catanzaro Study, GHS Gargano Heart Study; MI myocardial infarction, BMI body mass index, HbA1c glycated hemoglobin